REG - Abingdon Health PLC - Funding award to develop test for malaria parasite

Abingdon HealthAnnouncement

27/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250127:nRSa6716Ua&default-theme=true

RNS Number : 6716U  Abingdon Health PLC  27 January 2025

 

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the
publication of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public domain.

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Funding award to develop test for malaria parasite

 

Point-of-care rapid diagnostic test for Plasmodium vivax infection to be
developed for in-field testing

 

York, U.K. 27 January 2025: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and distributor of high quality and
effective rapid tests, announces that it has been awarded approximately
£800,000 as part of total project funding of EUR 5m to develop, and transfer
to manufacture, a new intervention for malaria elimination as part of a
distinguished group of Institut Pasteur (https://www.pasteur.fr/en) (and its
affiliates in Madagascar and Senegal), the Armauer Hansen Research Institute
(https://ahri.gov.et/) in Ethiopia, FIND (https://www.finddx.org/) , London
School of Hygiene & Tropical Medicine (https://www.lshtm.ac.uk/) (LSHTM)
and Walter and Eliza Hall Institute of Medical Research
(https://www.wehi.edu.au/) (WEHI).  The project is scheduled to begin in
February 2025 and be delivered over 24 months.

 

The funding to Abingdon Health, which will be provided by UK Research and
Innovation (UKRI) under the 'Horizon Europe Guarantee' scheme, is to allow the
Company to lead the development of a point-of-care (POC) rapid diagnostic test
(RDT) for Plasmodium vivax (P.vivax) infection to support in-field testing and
treatment to facilitate malaria control strategy.

 

The primary purpose of the PvSeroRDT (P. vivax Serological Rapid Detection
Test) project is to develop a POC RDT for field-based implementation that
replicates lab-based tests for the detection of P. vivax. Once the RDT has
successfully been developed, Abingdon Health will transfer the product to
diaTROPIX, a Senegalese manufacturing organisation based at Institut Pasteur
Dakar (https://institutpasteurdakar.sn/) . Establishing African-based
manufacturing is important in helping to build new infrastructure, aiming to
facilitate the preparation, management, and response to infectious diseases.
Abingdon Health is committed to ensuring the support of the scaling up,
transfer to manufacturing and support to diaTROPIX, to ensure they are well
equipped to deliver PvSeroRDT's to African communities, particularly those in
sub-Saharan Africa.

 

 

The PvSeroRDT project will contribute a robust POC diagnostic to the pipeline
in sub-Saharan Africa. The project is designed to address the World Health
Organisation's preferred product characteristic for P. vivax diagnosis, to
translate from an SME prototype to African-based industrial design, to test
clinical performance in several African sites, and to facilitate field
deployment. This will ultimately secure healthcare provider access to this
novel diagnostic, facilitating implementation of P. vivax serological testing
and treatment - a new intervention for malaria elimination.

 

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to have
won this grant award as part of a world-leading group of institutions. We are
excited to add Abingdon Health's RDT development and manufacturing scale-up
expertise to that of our distinguished group of partners. Working with the
Institut Pasteur, FIND, LSHTM, and WEHI gives us a great opportunity to
produce rapid tests to aid the management of malaria."

 

Dr Michael White, Director of Research at Institute Pasteur commented: "We are
very pleased to partner with Abingdon Health to develop and manufacture a new
rapid diagnostic test for Plasmodium vivax malaria that is poised to make an
important contribution to malaria elimination efforts."

 

The person responsible for arranging the release of this announcement on
behalf of the Company is Chris Hand, Executive Chairman of the Company.

 

Enquiries

 

 Abingdon Health plc                                                            www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                           Via Walbrook PR
 Chris Hand, Executive Chairman

 Zeus (Sole Broker and Nominated Adviser)                                         Tel: +44 (0) 20 3829 5000
 Chris Fielding / Alexandra Campbell-Harris (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                              (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
 Phillip Marriage                             +44 (0)7867 984 082

 

 

About Abingdon Health plc

Abingdon Health is a leading med-tech contract service provider offering its
services to an international customer base.

 

The Group's CDMO division (https://www.abingdonhealth.com/services/) offers
lateral flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format. Abingdon Health's
CDMO division has the internal capabilities to take lateral flow projects, in
areas such as infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing, from initial concept
through to routine and large-scale manufacturing; from "idea to commercial
success".

 

Abingdon Health's regulatory services companies, Compliance Solutions (Life
Sciences) (https://cslifesciences.com) and IVDeology
(https://www.ivdeology.co.uk) , provide a broad range of regulatory services
to the in vitro diagnostic and wider medical device industry, to support
customers in bringing products to market across a range of territories
including the USA, EU and the UK. Our consultancy services range from design,
implementation and maintenance of quality management systems, preparation of
technical files for regulatory approvals, part-time and interim management
support, auditing both internal and external, management reviews and
presentations, training and mentoring.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) e-commerce site offers consumers a range
of information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon Health's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland, such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEASFLAFDSEFA